Skip to content

Author

Xiao-Xiao Lai

We have 1 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database

Abstract Background Bexagliflozin and velagliflozin are currently the only sodium-glucose cotransporter 2 inhibitors approved by the United States Food and Drug Administration (FDA) for treating diabetes in cats. There are limited real-world safety reports on their associated adverse events (AEs). Hypothesis/Objectives...

Xiao-Xiao Lai, Mao-Hua Chen, Ya-Ping Huang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.